Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds that smaller biotechs are increasingly going the distance alone.

Over the past three years, an increasing proportion of new drug launches are the first for a given company, particularly in Orphan indications and other niche areas. ...